Therapeutic study of 90Y–DOTA-biotin with the pretargeting technique.
At the time of the experiment, the mice had sIL-2Rα levels of 1000 to 10 000 pg/mL. Mice in the control group did not receive any treatment, and mice in other groups received 140 μg HAT-SA pretargeting for 24 hours, 100 μg sCA for 4 hours, followed by different doses of90Y–DOTA-biotin: 0 μCi (0 MBq; Y-0), 100 μCi (3.7 MBq; Y-100), 175 μCi (6.475 MBq; Y-175), or 250 μCi (9.25 MBq; Y-250). (A) Growth of MET-1 tumor in SCID/NOD mice as shown by the serum concentrations of sIL-2Rα. Serum collections from the mice were taken at 2 days before and at 14 and 28 days after therapy, and the concentrations of sIL-2Rα were measured. (B) Platelet count as measured weekly in MET-1 tumor-bearing SCID/NOD mice. (C) Kaplan-Meier survival plot of the MET-1 tumor-bearing SCID/NOD mice.
